Phospholipase A2 Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention

EA Dennis, J Cao, YH Hsu, V Magrioti… - Chemical …, 2011 - ACS Publications
1.1. Discovery of the Phospholipase A2 Superfamily Phospholipases represent one of the
earliest enzyme activities to be identified and studied, and the phospholipase A2 (PLA2) …

The metabolic serine hydrolases and their functions in mammalian physiology and disease

JZ Long, BF Cravatt - Chemical reviews, 2011 - ACS Publications
Serine hydrolases (SHs) consist of> 200 enzymes in humans characterized by the presence
of an active site serine that is used for the hydrolysis of substrates. The membership of this …

Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists

MH Davidson, CM Ballantyne, TA Jacobson… - Journal of clinical …, 2011 - Elsevier
The National Cholesterol Education Program Adult Treatment Panel guidelines have
established low-density lipoprotein cholesterol (LDL-C) treatment goals, and secondary non …

Inflammation and atherosclerosis—revisited

S Pant, A Deshmukh, GS GuruMurthy… - Journal of …, 2014 - journals.sagepub.com
Atherogenesis has been traditionally viewed as a metabolic disease representing arterial
obstruction by fatty deposits in its wall. Today, it is believed that atherogenesis involves …

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial

JJP Kastelein, KC Maki, A Susekov, M Ezhov… - Journal of clinical …, 2014 - Elsevier
Background Omega-3 fatty acids in free fatty acid form have enhanced bioavailability, and
plasma levels are less influenced by food than for ethyl ester forms. Objective The aim was …

Metabolism and atherogenic disease association of lysophosphatidylcholine

G Schmitz, K Ruebsaamen - Atherosclerosis, 2010 - Elsevier
Lysophosphatidylcholine (LPC) is a major plasma lipid that has been recognized as an
important cell signalling molecule produced under physiological conditions by the action of …

Chronic inflammatory diseases and cardiovascular risk: a systematic review

I Roifman, PL Beck, TJ Anderson, MJ Eisenberg… - Canadian Journal of …, 2011 - Elsevier
Despite recent advancements in the treatment of coronary artery disease (CAD), it remains
the number one cause of death in the world. While traditional risk factors partially account for …

Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines

MH Davidson, MA Corson, MJ Alberts… - The American journal of …, 2008 - Elsevier
A consensus panel was formed to review the rapidly emerging literature on the vascular-
specific inflammatory marker lipoprotein-associated phospholipase A2 (Lp-PLA2) and to …

Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group

LA Leiter, DH Fitchett, RE Gilbert, M Gupta… - Canadian Journal of …, 2011 - Elsevier
The concepts of “cardiometabolic risk,”“metabolic syndrome,” and “risk stratification” overlap
and relate to the atherogenic process and development of type 2 diabetes. There is …

Oxidized phospholipids and lipoprotein‐associated phospholipase A2 (Lp‐PLA2) in atherosclerotic cardiovascular disease: An update

D Pantazi, C Tellis, AD Tselepis - Biofactors, 2022 - Wiley Online Library
Inflammation and oxidative stress conditions lead to a variety of oxidative modifications of
lipoprotein phospholipids implicated in the occurrence and development of atherosclerotic …